Press Releases
-
Sep 15, 2020
- J.P. Morgan U.S. All Stars Conference on September 16 at 11:00am ET/4:00BSTBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual conferences. An audio webcast of the presentations will be available live. You...
-
Sep 11, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Lynda Polgreen, MD, MS, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA will present...
-
Sep 8, 2020Statistically Significant Increases in Height Z Score
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that The Lancet has published online results from a randomized, double-blind, phase 3, placebo-controlled, multicenter trial for...
-
Sep 8, 2020- Baird 2020 Global Healthcare Conference on September 9 at 11:25am ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You...
-
Aug 20, 2020Potential first treatment for achondroplasia in the United States
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vosoritide, an investigational,...
-
Aug 19, 2020FDA Introduces New Recommendation for 2-Year Annualized Bleeding Rate (ABR) as Primary Endpoint for Ongoing Phase 3 Study 270-301
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the Company's Biologics License Application...
-
Aug 13, 2020Potential first medicine to treat Achondroplasia in EU
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for vosoritide, an...
-
Aug 10, 2020- 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer, and Brian Mueller, Executive Vice President, Chief Financial...
-
Aug 4, 2020- Impact of the Coronavirus (COVID-19) Pandemic as Expected in the Second Quarter; 2020 Full-Year Revenue Guidance Reaffirmed Assuming Demand Patterns Return to Normal in Late 2020
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2020 2019 % Change 2020 2019 % Change Total Revenues $ 429.5
-
Jul 23, 2020If approved, vosoritide would be the first medicine to treat Achondroplasia in EU
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vosoritide, an...
-
Jul 21, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday,...
-
Jun 29, 2020Andrea L. Acosta to be Promoted to Group Vice President, Chief Accounting Officer
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President,...
-
Jun 23, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer, will participate...
Jun 17, 202096% Mean Reduction in Factor VIII UsageBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an...
-
Jun 3, 2020- Jefferies Virtual Healthcare Conference on June 4
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs, M.D., President, Worldwide Research & Development; and...
-
May 31, 2020All Study Participants Remain off Prophylactic Therapy
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene...
-
May 19, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the initial purchasers of the previously announced offering of its 1.25% Senior Subordinated Convertible Notes due 2027 in a...
-
May 11, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the pricing of $550.0 million aggregate principal amount of 1.25% senior subordinated convertible notes due 2027 in a private placement...
-
May 11, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of senior...
-
May 6, 2020- Bank of America Global Research Health Care Conference on May 14
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the Bank of America Global Research Health Care Conference on May 14, 2020 at 2:20pm ET and the RBC...
-
May 3, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform...
-
Apr 29, 2020- U.S. Marketing Application for Valoctocogene Roxaparvovec for Severe Hemophilia A Accepted by FDA under Priority Review with Prescription Drug User Fee Act (PDUFA) action date of August 21, 2020
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2020 2019 % Change Total Revenues $ 502.1 $ 400.7 25 % Net Product Revenues...
-
Apr 22, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Apr 21, 2020Robert Baffi, Ph.D., President, Global Manufacturing and Technical Operations Moves Toward Retirement and Continues in Full-Time Capacity as Special Advisor to the Chairman and CEO During Transition Before Retiring
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical...
-
Apr 14, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
